04Jun
Cannabis-Derived Ingredients in FDA-Regulated Products: More Questions than Answers at FDA’s May 2019 Public Hearing
As most folks with any interest in the burgeoning cannabidiol (CBD) industry likely know, on May 31, 2019, the Food and Drug Administration held a public hearing “to obtain scientific data and information about the safety, manufacturing, product...
By:
Mintz - Consumer Product Safety Viewpoints
Related
The allocation of risks arising from contaminated sites, irrespective of their location worldwide, i...
Read More >
In 2016, Florida joined the ranks of states that legalized medical marijuana after voters approved a...
Read More >
Yesterday, the U.S. Department of Labor (DOL) released its much-anticipated final overtime rule, inc...
Read More >
Welcome to your weekly update from the Allen & Overy Pensions team, bringing you up to speed on the ...
Read More >
As previously blogged last week, Burns & Levinson hosted its third annual State of the Cannabis Indu...
Read More >
Our Antitrust and M&A Groups analyze this year’s Federal Trade Commission updates to its thresholds...
Read More >